The nitric oxide pathway and possible therapeutic options in pre-eclampsia

Area of Science:

• Obstetrics and Gynecology
• Cardiovascular Research
• Pharmacology

Background:

• Pre-eclampsia is a severe pregnancy disorder characterized by endothelial dysfunction and reduced nitric oxide (NO) bioavailability.
• This pathophysiology contributes to maternal and fetal complications, often necessitating preterm delivery and increasing morbidity/mortality risks.
• Current treatments lack the ability to reverse underlying pathophysiological changes.

Purpose of the Study:

• To review the clinical research status of therapeutic modalities targeting the nitric oxide-soluble guanylyl cyclase pathway in pre-eclampsia.
• To explore the potential of enhancing NO bioavailability as a treatment strategy.
• To evaluate drugs that modulate the NO pathway for pre-eclampsia management.

Main Methods:

• Review of clinical research on drugs affecting the nitric oxide-soluble guanylyl cyclase pathway.
• Focus on nitric oxide donors (organic nitrates, S-nitrosothiols), L-arginine, and phosphodiesterase-5 inhibitors (sildenafil).
• Analysis of novel inhibitors of NO donor metabolism.

Main Results:

• Various drugs targeting the NO pathway show potential for increasing NO bioavailability.
• Nitric oxide donors, L-arginine, and sildenafil are discussed regarding their advantages and limitations.
• The review outlines the current scope for these agents in pre-eclampsia treatment.

Conclusions:

• Therapeutic strategies targeting the nitric oxide pathway offer a promising avenue for managing pre-eclampsia.
• Further development is needed to establish these modalities as effective treatments.
• Addressing endothelial dysfunction via NO enhancement could mitigate maternal and neonatal risks.